All In Biotech

Drug Trial Radar · NCT07947940

Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With Tafamidis

ASSESSING PROGNOSTIC VALUE OF MARKERS OF CARDIAC DISEASE PROGRESSION IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) PATIENTS TREATED WITH TAFAMIDIS - A NON-INTERVENTIONAL, RETROSPECTIVE COHORT STUDY USING REAL-WORLD DATA IN THE UNITED STATES

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1

Planned (sponsor's estimate)

Start

Nov 24, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.

Conditions

  • ATTR-CM (Transthyretin Amyloid Cardiomyopathy)

Interventions

  • TafamidisDrug

    As provided in real-world routine clinical practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to All cause MortalityTime frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
  2. Time to Cardiovascular Mortality (CV)Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)
  3. Time to First (Cardiovascular, Non-Cardiovascular) HospitalizationTime frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019-June 30, 2026)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.